#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Cannabis hyperemesis syndrome (CHS) is an increasingly recognized condition characterized by cyclic nausea, vomiting, and abdominal pain in chronic cannabis users, with incidence rising as cannabis potency and availability increase. The syndrome typically presents in three phases: a prodromal phase with mild nausea and decreased appetite, a hyperemetic phase with severe vomiting and dehydration, and a recovery phase following cessation of use. CHS is thought to result from desensitization of cannabinoid receptors in the gut and brain with chronic exposure, particularly at high doses of tetrahydrocannabinol (THC), making it increasingly relevant as patients access more potent products. Clinicians should maintain a high index of suspicion for CHS in patients presenting with intractable nausea and vomiting who report regular cannabis use, as the condition is often misdiagnosed or attributed to other causes, delaying appropriate treatment. Diagnosis is primarily clinical, as no specific laboratory or imaging findings are pathognomonic, and definitive treatment requires complete cannabis cessation rather than pharmacologic intervention. Patients presenting with chronic nausea and vomiting should be routinely questioned about cannabis use frequency and product potency, and counseled that cessation is the only proven resolution for this increasingly common adverse effect.
“Cannabinoid hyperemesis syndrome is real and I’m seeing it more frequently in my practice, particularly in patients using high-potency products daily, and the key clinical pearl is that these patients often don’t connect their symptoms to cannabis use because they’re using it to treat nausea in the first place, creating a diagnostic trap that delays proper treatment.”
💊 As cannabis use becomes increasingly normalized and potency continues to rise due to legalization and market competition, clinicians should be aware of cannabinoid hyperemesis syndrome (CHS) as a potential diagnosis in patients presenting with cyclic nausea and vomiting, particularly those with heavy or daily cannabis use. While CHS remains relatively uncommon in the general population, the syndrome’s prevalence appears to be increasing in line with higher-potency products and greater consumption frequency, making it important for providers to include cannabis use patterns in their assessment of recurrent nausea and vomiting. It is worth noting that CHS can be difficult to distinguish from other causes of cyclic vomiting, and many patients may not initially disclose cannabis use, so a thorough and non-judgmental substance use history is essential. The pathophysiology remains incompletely understood and may involve dose-dependent effects of tetrahydrocannabinol on
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
